Researchers believe that focusing on MCFA catabolism could exploit a key metabolic feature of an aggressive form of brain and spinal cord cancer. The preclinical study reveals an important new understanding of metabolism in glioblastoma and supports the development of MCAD inhibitors as a novel treatment strategy.